deltatrials
Completed PHASE3 NCT01163032

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon Versus Placebo in Totally Blind Subjects With N24HSWD Followed by an OLE Phase

Sponsor: Vanda Pharmaceuticals

Conditions Non-24-Hour Sleep-Wake Disorder
Interventions Placebo tasimelteon
Updated 7 times since 2017 Last updated: Oct 15, 2014 Started: Aug 31, 2010 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

A PHASE3 clinical study on Non-24-Hour Sleep-Wake Disorder, this trial is completed. The trial is conducted by Vanda Pharmaceuticals and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vanda Pharmaceuticals
Data source: Vanda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States, Atlanta, United States, Berlin, Germany, Bochum, Germany, Boston, United States, Brandon, United States, Chesterfield, United States, Chevy Chase, United States, Cincinnati, United States, Columbia, United States and 18 more location s